Hansoh Pharmaceutical Group Company Limited
翰森製藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3692)

VOLUNTARY ANNOUNCEMENT

LICENSE AGREEMENT WITH GLENMARK

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that, on December 16, 2025 (after trading hours), Jiangsu Hansoh Pharmaceutical Group Co., Ltd.* (江蘇豪森藥業集團有限公司) (the "**Licensor**"), a wholly-owned subsidiary of the Company, entered into an exclusive license, collaboration and distribution agreement (the "**License Agreement**") with Glenmark Specialty S.A. (the "**Licensee**") for Aumolertinib (阿美替尼), a third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ("**EGFR-TKI**") for the treatment of non-small cell lung cancer ("**NSCLC**").

Under the License Agreement, the Licensor shall grant an exclusive license to the Licensee to develop and commercialize Aumolertinib across its licensed territories: the Middle East and Africa, Southeast & South Asia, Australia, New Zealand, Russia/CIS and a few selected Caribbean countries covered by the License Agreement. The Licensor will receive an upfront payment, followed by potential regulatory and commercial milestone payments possibly cumulating to over US$1 billion, in addition to tiered royalties on net sales in the licensed territories.

ABOUT AUMOLERTINIB

Ameile (阿美樂®) (Aumolertinib Mesilate Tablets) is the first original third-generation EGFR-TKI innovative drug in China. It has been approved for four indications in China, namely: in March 2020, it was approved for the treatment of patients with locally advanced or metastatic NSCLC with T790M mutation, who have progressed on or after EGFR-TKI therapy; in December 2021, it was approved as the first-line treatment for adult patients with locally advanced or metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitute mutation positive; in March 2025, it was approved for the treatment of patients with locally advanced, unresectable NSCLC whose disease has not progressed following definitive platinum-based chemoradiotherapy whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitute mutations; in May 2025, it was approved for the adjuvant treatment of adult patients with stage II to IIIB NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, and who have undergone tumor resection with or without prior adjuvant chemotherapy as determined by their physician. Additionally, in June 2025, Aumolertinib (trade name in the United Kingdom: Aumseqa®) was approved by the Medicines and Healthcare Products Regulatory Agency in the United Kingdom (MHRA) for marketing.

ABOUT GLENMARK

The Licensee is a wholly-owned subsidiary of Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK), which is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments, with a focus on therapeutic areas of respiratory, dermatology and oncology.

LISTING RULES IMPLICATION

To the best of the Directors' knowledge, information and belief having made all reasonable enquiry, the Licensee and its ultimate beneficial owner are independent of, and are not connected with, the Company and its connected persons (as defined in the Listing Rules). The transactions contemplated under the License Agreement are of a revenue nature in the ordinary and usual course of business of the Group and do not constitute any notifiable transactions or connected transactions of the Company under the Listing Rules.

The License Agreement is subject to necessary regulatory filings. The shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By Order of the Board
Hansoh Pharmaceutical Group Company Limited
Zhong Huijuan
Chairlady

Hong Kong, December 16, 2025

As at the date of this announcement, the Board comprises Ms. Zhong Huijuan as chairlady and executive director, Ms. Sun Yuan and Dr. Lyu Aifeng as executive directors, and Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai and Ms. Yang Dongtao as independent non-executive directors.

* *For identification purposes only*